Pipeline
Place: Japan
| Development No. | Therapeutic Category | Stage |
|---|---|---|
| T-705 | Antiviral agent (Anti-influenza virus agent) | NDA filing |
| T-614 | Antirheumatic agent | NDA filing |
| T-5224 | Antirheumatic agent (AP-1 inhibitor) | Phase 2 |
| T-3811 | New type injectable quinolone synthetic antibacterial agent | Phase 1 |
| T-1106 | Antiviral agent (Anti HCV agent) | Non-clinical studies |
(As of January 2012)
Place: Overseas
| Development No. | Therapeutic Category | Stage |
|---|---|---|
| T-3811 | New type quinolone synthetic antibacterial agent | Preparing to file |
| T-817MA | Treatment for Alzheimer's disease | Phase 2 |
| T-705 | Antiviral agent (Anti-influenza virus agent) | Phase 2 |
| T-2307 | Antifungal agent | Phase 1 |
| T-5224 | Antirheumatic agent (AP-1 inhibitor) | Phase 1 |
FUJIFUILM group will conduct development in the foreign country.
(As of January 2012)
